Education
About Us
Working with TipRanks
Follow Us
Bioatla, Inc. (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$0.13 - $1.43
Previous CloseN/A
Volume775.41K
Average Volume (3M)2.70M
Market Cap
$18.37M
Enterprise Value$12.36M
Total Cash (Recent Filing)$8.32M
Total Debt (Recent Filing)$6.18M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding74,263,740
10 Day Avg. Volume1,792,487
30 Day Avg. Volume2,698,729
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.01
Price to Sales (P/S)2.61
P/FCF Ratio-0.40
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.99
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$4.00Price Target Upside2005.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway ClarityFDA alignment on a Phase 3 registrational design provides a clear, durable pathway to potential accelerated and full approval for OSV in OPSCC. This reduces regulatory execution risk, supports future partnering/commercial plans, and preserves value capture if pivotal outcomes are positive.
Strategic Non-Dilutive FundingThe $40M oncology SPV funds registrational Phase 3 work while sharing development and commercialization costs. Retaining majority SPV ownership keeps upside for BioAtla, reduces immediate cash burden, and extends runway without a traditional dilutive equity raise.
Platform Validation & CollaborationsA paid development milestone and multiple encouraging clinical signals across CAB programs (OSV, EpCAM TCE, MEKV) validate the CAB platform, strengthening licensing/partnering leverage and supporting a multi-program development strategy that can diversify long-term value drivers.
Bears Say
Deteriorated Balance SheetNegative shareholders' equity reflects accumulated losses and materially weaker solvency, constraining financing options and increasing bankruptcy or restructuring risk. This structural weakness limits strategic flexibility and heightens reliance on external capital over the medium term.
High Cash Burn / Limited RunwaySustained large negative operating and free cash flows indicate ongoing need for external financing to fund R&D and trials. With modest cash on hand, the company faces elevated dilution or deal-dependency risk, which can disrupt long-term development continuity if funding stalls.
Listing & Governance RiskActive disputes over share-structure maneuvers and continued Nasdaq compliance questions present structural governance and listing risks. Potential delisting or contentious capital actions could impair access to public markets, increase financing costs, and distract management from execution.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $0.13 and its highest was $1.43 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $18.37M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 16 days.
How were Bioatla, Inc.’s earnings last quarter?
Bioatla, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.027.
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Undervalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 74,263,740 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Bioatla, Inc. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went up 19.879%.
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Company Deck
BCAB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic transactions, and market potential for BioAtla's programs, with robust data supporting their CAB platform's potential. However, financial challenges were noted, including increased net loss and decreased cash reserves.View all BCAB earnings summariesBCAB Stock 12 Month Forecast
Average Price Target
$4.00
▲(2005.26% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
8.59% Insiders
3.54% Mutual Funds
0.92% Other Institutional Investors
83.09% Public Companies and
Individual Investors